AZN - AstraZeneca PLC

NYSE - NYSE Delayed Price. Currency in USD
34.39
-0.23 (-0.66%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close34.62
Open34.57
Bid0.00 x 0
Ask0.00 x 0
Day's Range34.35 - 34.71
52 Week Range25.55 - 35.60
Volume2,575,280
Avg. Volume4,949,596
Market Cap84.17B
Beta0.65
PE Ratio (TTM)22.56
EPS (TTM)1.52
Earnings DateN/A
Forward Dividend & Yield0.90 (2.59%)
Ex-Dividend Date2017-08-09
1y Target Est37.37
Trade prices are not sourced from all markets
  • Reuters19 hours ago

    AstraZeneca among backers as Swiss cancer biotech raises $200 million

    An unlisted Swiss biotech company focused on developing "armed antibodies" to fight cancer has raised $200 million (£152 million) in a funding round backed by AstraZeneca (AZN.L) and other private backers. The new money will allow ADC Therapeutics (ADCT) to advance two experimental drugs into clinical trials next year, which could be used to seek regulatory approval, as well as funding earlier-stage research. The latest financing means ADCT has raised a total of $455 million since its inception in 2012, when it was founded by Auven Therapeutics.

  • US FDA Approves New Easy-to-Use, Once-Weekly BYDUREON® BCise™ Injectable Medicine for Patients with Type-2 Diabetes
    Business Wire20 hours ago

    US FDA Approves New Easy-to-Use, Once-Weekly BYDUREON® BCise™ Injectable Medicine for Patients with Type-2 Diabetes

    AstraZeneca today announced that the US Food and Drug Administration has approved BYDUREON® BCise™ injectable suspension, a new formulation of BYDUREON® injectable suspension in an improved once-weekly, single-dose autoinjector device for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines in addition to diet and exercise, to improve glycemic control.

  • Cancer Treatment Update: Second Gene Therapy Receives Approval
    Zacks3 days ago

    Cancer Treatment Update: Second Gene Therapy Receives Approval

    The FDA approved Gilead's Yescarta for DLBCL, second CAR-T therapy in the United States. The regulatory authority also granted priority review to label expansion applications for four major cancer drugs.

  • AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review
    Zacks5 days ago

    AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review

    AstraZeneca (AZN) said that the FDA has granted priority review to its sNDA for two cancer drugs, Lynparza for an advanced breast cancer indication and Imfinzi for an earlier stage of lung cancer.

  • Business Wire6 days ago

    AstraZeneca Announces New Data Showing US Preterm Infants at Significantly Greater Risk of RSV Hospitalizations Following 2014 Guidance Change

    AstraZeneca today announced new results of a study that investigated respiratory syncytial virus hospitalization risk and costs during the 2014-2016 RSV seasons compared to the 2012-2014 RSV seasons.

  • Financial Times6 days ago

    [$$] Akzo/AstraZeneca: the chemical brothers

    A company incorporating bits of defunct UK multinational Imperial Chemical Industries sends a US suitor packing. Then it spends years coaxing its shares back towards the offer price. It could be AstraZeneca. ...

  • Market Realist6 days ago

    What AstraZeneca’s 3Q17 Performance Tells Us

    AZN stock rose ~0.9% in 3Q17 and has risen ~26.9% YTD (year-to-date) as of October 16.

  • Benzinga6 days ago

    Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever

    Analysts at Citi hold a bullish rating on Merck & Co., Inc. (NYSE: MRK ). The firm's Andrew Baum upgraded Merck's stock from Neutral to Buy "for the first time," with a price target boosted from ...

  • Business Wire6 days ago

    US FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review

    AstraZeneca and Merck & Co., Inc., today announced that the US Food and Drug Administration has accepted and granted priority review for a supplemental New Drug Application for the use of LYNPARZA® tablets in patients with germline BRCA-mutated , HER2-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic settings.

  • Reuters6 days ago

    Astra and Merck win speedy review for Lynparza in breast cancer

    U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during the first quarter of 2018. The medicine, which is being jointly developed and marketed with Merck under a deal struck in July, is the first poly ADP-ribose polymerase (PARP) drug to be considered for use outside ovarian cancer. Lynparza is also being tested in prostate and pancreatic cancers, the two companies said on Wednesday.

  • Business Wire7 days ago

    US FDA Accepts Supplemental Biologics License Application for IMFINZI® (durvalumab) in Locally Advanced, Unresectable Non-Small Cell Lung Cancer

    AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration has accepted a supplemental Biologics License Application for IMFINZI® for the treatment of patients with locally advanced, unresectable non-small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy.

  • Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion
    Zacks8 days ago

    Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion

    Foreign markets remain undeterred by discouraging events, notching up weekly gains.

  • Bloomberg8 days ago

    Drug Companies Fear Brexit Will Hit Medicine Trade

    Time is running short for a Brexit agreement that will allow the free movement of medicines through the U.K. and the rest of the European Union.

  • 5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings
    Zacks10 days ago

    5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings

    The pharma/biotech sector has a number of things going in its favor.

  • Cancer Space Update: Lung & Breast Cancer Studies in Focus
    Zacks11 days ago

    Cancer Space Update: Lung & Breast Cancer Studies in Focus

    While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.

  • Lilly's Verzenio Gets Priority Review in First-Line Setting
    Zacks11 days ago

    Lilly's Verzenio Gets Priority Review in First-Line Setting

    Eli Lilly and Company (LLY) announced that the FDA has granted priority review to its new drug application for Verzenio (abemaciclib) for the first-line treatment of advanced breast cancer.

  • AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation
    Zacks15 days ago

    AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation

    AstraZeneca (AZN) obtained Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.

  • Business Wire15 days ago

    TAGRISSO® (osimertinib) Granted Breakthrough Therapy Designation by US FDA for the 1st-Line Treatment of Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer

    AstraZeneca today announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation for TAGRISSO® for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer .

  • What's Behind AstraZeneca's September Rebound?
    Motley Fool16 days ago

    What's Behind AstraZeneca's September Rebound?

    AstraZeneca's shares finally broke out of their slump in September.

  • These Biotechs Slump As Report Suggests Discounting Their Drugs
    Investor's Business Daily20 days ago

    These Biotechs Slump As Report Suggests Discounting Their Drugs

    AstraZeneca and Tesaro stocks were in a slump Tuesday, a day after an institute doubted the cost-effectiveness of their cancer drugs.

  • Tell us how Brexit will work, British companies demand
    Reuters22 days ago

    Tell us how Brexit will work, British companies demand

    British companies including pharmaceuticals giant AstraZeneca urged the government on Monday to agree a three-year Brexit transitional deal to ease the uncertainty hampering investment decisions and the economy. Britain's biggest companies have become increasingly alarmed by the slow progress of Brexit negotiations and the prospect the country could crash out of the world's biggest trading bloc without a deal in 2019. Prime Minister Theresa May vowed in a speech last month to seek a two-year transition deal to help reduce the disruption, but her efforts were overshadowed by a challenge from Foreign Secretary Boris Johnson who has set out his own terms for Britain leaving the European Union.

  • Reuters22 days ago

    Drugs firm AstraZeneca wants three-year Brexit transition

    British pharmaceuticals giant AstraZeneca (AZN.L) wants a transition period of at least three years when Britain leaves the European Union in 2019 and more clarity on what will happen in the longer term, its chairman said on Monday. Uncertainty about what Britain's relations with the EU will look like after March 2019 are hurting investment in the world's fifth largest economy. AstraZeneca Chairman Leif Johansson said the firm wanted "at least three years" as a transition period, "and very early in that period, we need to know what to expect in years four, five and six," he said told the Swedish daily Dagens Nyheter.

  • Drugs firm AstraZeneca wants three-year Brexit transition
    Reuters22 days ago

    Drugs firm AstraZeneca wants three-year Brexit transition

    British pharmaceuticals giant AstraZeneca (AZN.L) wants a transition period of at least three years when Britain leaves the European Union in 2019 and more clarity on what will happen in the longer term, its chairman said on Monday. Uncertainty about what Britain's relations with the EU will look like after March 2019 are hurting investment in the world's fifth largest economy. AstraZeneca Chairman Leif Johansson said the firm wanted "at least three years" as a transition period, "and very early in that period, we need to know what to expect in years four, five and six," he said told the Swedish daily Dagens Nyheter.

  • Should You Be Tempted To Buy AstraZeneca PLC (LSE:AZN) At Its Current Price?
    Simply Wall St.25 days ago

    Should You Be Tempted To Buy AstraZeneca PLC (LSE:AZN) At Its Current Price?

    AstraZeneca PLC (LSE:AZN) is trading with a trailing P/E of 21.6x, which is lower than the industry average of 38.5x. While AZN might seem like an attractive stock to buy,Read More...